<DOC>
	<DOCNO>NCT01408381</DOCNO>
	<brief_summary>Phase II Clinical Trial , prospective , multicenter , open , randomize , parallel-group control three level dose . The hypothesis test propose mononuclear cell bone marrow provide progenitor cell regenerative capacity besides secrete several angiogenic factor , implantation ischemic tissue element contribute angiogenesis tissue regeneration recovery circulation affect limb .</brief_summary>
	<brief_title>Intra-arterial Infusion Autologous Bone Marrow Mononuclear Cells Non-diabetic Patients With Critical Limb Ischemia ( CLI ) .</brief_title>
	<detailed_description>The study population consist total 44 non-diabetic patient chronic critical ischemia least one low limb ( CLI ) without possibility revascularization . In experimental group include total 33 patient divide three level dose , 11 patient level ( increase dose mononuclear cell autologous bone marrow ) 11 patient control group . - 11 patient group 1 receive cell therapy , receive conventional treatment , act control group . - 11 patient group 2 receive 1x108 autologous bone marrow mononuclear cell . - 11 patient group 3 receive 5x108 autologous bone marrow mononuclear cell . - 11 patient group 4 receive 1x109 autologous bone marrow mononuclear cell . The cell therapy drug administer intra-arterially case . Patients evaluate clinical , radiological angiological method ( ankle / brachial pressure index , transcutaneous oxygen pressure , perimeter calf muscle , presence ulcer , oximetry digital arteriography ) . Patients receive concomitant drug treatment establish good clinical practice , undoubtedly could possible improvement occurs due drug treatment . It estimate inclusion period approximately 42 month , follow-up patient six month . Therefore total duration study forty eight month entry first patient end follow-up period last patient include . The primary variable improvement vascularisation treat limb determine clinical , angiographic angiologist parameter . Study objective : • Main objective : To evaluate safety feasibility autotransplantation autologous bone marrow mononuclear cell administer intra-arterially non-diabetic patient critical chronic ischemia lower limb without possibility either revascularization therapeutic alternative . Secondary objective : 1 . To compare effect three increase dose mononuclear cell autologous bone marrow recovery clinical , angiographic angiologist parameter non-diabetic patient critical chronic ischemia lower limb control group apply conventional treatment . 2 . To analyze complication regenerative therapy , route administration / study procedure .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Patients sex age ≥ 18 ≤ 89 year . Nondiabetic . Infrapopliteal atherosclerotic vascular disease severe severe claudication RutherfordBecker grade I3 , II , III , least one low limb . The chronic critical ischemia lower limb define persistent / recur pain require analgesia / nonhealing ulcer present &gt; 4 week , evidence improvement conventional therapy / walk test ( stress test ) 16 minute two exercise test separate least 2 week / anklebrachial index rest &lt; 0.8 . Inability endovascular surgical revascularization recommend TransAtlantic InterSociety Consensus ( TASC ) . Failure revascularization surgical perform least 30 day , either persistently entry critical ischemia phase . Life expectancy &gt; 2 year . Not expect major amputation limb treat next 6 month inclusion . Normal laboratory parameter , define : 1 . Leukocytes ≥ 3000 2 . Neutrophils ≥ 1500 3 . Platelets ≥ 100,000 4 . Aspartate aminotransferase AST ) / Alanine aminotransferase ( ALT ) ≤ 2.5 standard range institution . 5 . Creatinine ≤ 2.5 mg / dl Patients give write informed consent participate study . Women childbearing potential must negative result pregnancy test follow standard procedure hospital perform time inclusion study agree use medically approve method contraception duration study . History malignancy hematologic disease ( myeloproliferative disease , myelodysplastic syndrome leukemia ) Patients uncontrolled hypertension ( define blood pressure &gt; 180/110 one occasion ) . Severe heart failure ( New York Heart Association IV ) . Patients malignant ventricular arrhythmia unstable angina . Diagnosis deep vein thrombosis previous 3 month . Active infection gangrene wet day infusion mononuclear bone marrow cell . Corporal mass index ( BMI ) &gt; 40 kg/m2 . Patients diagnosis alcoholism time inclusion . Proliferative retinopathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Critical Limb Ischemia ( CLI )</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>Bone marrow mononuclear cell</keyword>
</DOC>